$16.86
-0.19 (-1.11%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DCTH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 observational · 1 expanded access
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, AQR CAPITAL MANAGEMENT LLC, Man Group plc, D. E. Shaw & Co., Inc., +4 more) · FINRA short interest 7.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant DiseaseNCT06875128hPFSRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) | Metastatic Breast Cancer in the Liver | 90 | May 2029 | ≤ 1,016 d | 2026-06-01 |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseaseNCT06607458hPFSRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone | Refractory Metastatic Colorectal Cancer | 90 | Dec 2026 | ≤ 134 d | 2026-06-01 |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaNCT05022901Adverse EventsOpen-label · Treatment | Phase 3 | Active, not recruiting | Combination product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) | Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | 30 | 2024-03-01 | — | 2023-12-21 |
| Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572Objective Response Rate (ORR) as determined by Independent Central Review CommitteeOpen-label · Treatment | Phase 3 | Completed | Combination product: Melphalan/HDS | Melanoma, Ocular | 102 | 2023-05-18actual | — | 2023-12-21 |
| Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaNCT03086993Overall SurvivalRandomized · Open-label · Treatment | Phase 2/3 | Unknown status | Combination product: Melphalan/HDS · Drug: Cisplatin and Gemcitabine | Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | 295 | Jan 2023 | — | 2022-03-24 |
| Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic MalignancyNCT03266042observationalGather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). | — | Unknown status | — | Hepatic Malignant Neoplasm Primary Non-Resectable | 200 | Jan 2020 | — | 2018-09-11 |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaNCT02415036Objective response rate in percentage of Melphalan/HDS treatmentNon-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Limited enrollment | Device: Delcath Hepatic Delivery System · Drug: Melphalan | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 17 | Oct 2018actual | — | 2022-10-17 |
| Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCCNCT02406508Number of patients with adverse events after treatment with Melphalan/HDS.Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: No enrollment in the study | Device: Melphalan/HDS · Drug: Sorafenib | Hepatocellular Carcinoma (HCC) | 0 | Dec 2017actual | — | 2017-12-18 |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerNCT00096083To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignanciesOpen-label · Treatment | Phase 2 | Completed | Drug: isolated perfusion, melphalan | Cancer | 56 | Aug 2012actual | — | 2013-10-23 |
| Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaNCT00324727Hepatic progression free survivalRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: melphalan, regional chemotherapy, systemic chemotherapy · Procedure: hepatic artery embolization | Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer | 93 | Aug 2012actual | — | 2021-06-21 |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to LiverNCT01728051expanded access | — | No longer available | Drug: Melphalan · Device: Percutaneous Hepatic Perfusion | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | — | — | — | 2013-10-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19